Novo Nordisk A/S $NVO Shares Bought by RFG Advisory LLC

Posted by Geri Gentry on Sep 10th, 2026

RFG Advisory LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 49.7% during the second quarter, HoldingsChannel.com reports. The firm owned 66,135 shares of the company’s stock after purchasing an additional 21,962 shares during the period. RFG Advisory LLC’s holdings in Novo Nordisk A/S were worth $3,171,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. Scarborough Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Transamerica Financial Advisors LLC lifted its position in shares of Novo Nordisk A/S by 201.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after buying an additional 403 shares in the last quarter. Continuum Advisory LLC purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $38,000. Finally, Johnson Financial Group Inc. grew its stake in Novo Nordisk A/S by 128.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock valued at $38,000 after acquiring an additional 384 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 1.2%

Shares of Novo Nordisk A/S stock opened at $44.62 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The stock’s 50 day simple moving average is $47.76 and its 200-day simple moving average is $43.68. The stock has a market cap of $199.23 billion, a P/E ratio of 10.91, a P/E/G ratio of 1.52 and a beta of 0.74. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The firm had revenue of $11.98 billion during the quarter. Analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a $0.5786 dividend. This represents a yield of 258.0%. The ex-dividend date was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is presently 20.05%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: Oral Wegovy moves closer to China launch: Chinese regulators accepted Novo Nordisk’s marketing application for oral Wegovy, opening a potential route into China’s projected $4.46 billion GLP-1 market. Acceptance is an important regulatory step, although approval and commercial success are not guaranteed. Can Oral Wegovy Help Novo Nordisk Capture China’s $4.46 Billion GLP-1 Opportunity?
Positive Sentiment: Promising pediatric obesity data: A Phase 3 study found weekly semaglutide helped reduce BMI in children with obesity; 40.4% were no longer classified as having obesity after 68 weeks. The results could support future regulatory expansion and create another sizable market for Wegovy. Novo Nordisk’s Semaglutide Meets Goal in Pediatric Obesity Study
Positive Sentiment: Share repurchases remain supportive: Novo Nordisk’s continuing buyback program provides a source of demand for the stock and may help offset some investor concerns while the company works through its pipeline challenges. Novo Nordisk’s September Tightrope
Neutral Sentiment: Valuation debate continues: The stock trades well below its 2024 peak, attracting bargain-hunting interest, but investors remain divided over whether the discount adequately reflects slower growth, competition from Eli Lilly and uncertainty surrounding the next generation of obesity medicines.
Negative Sentiment: Cardiovascular pipeline setback: Novo Nordisk halted two heart-drug trials, weakening confidence in its efforts to diversify beyond diabetes and obesity and prompting at least one analyst rating downgrade. Novo Nordisk: STEP Young Wins, But Heart Trials Just Got Halted
Negative Sentiment: Competitive and strategic concerns: Novo’s new chief executive has expressed caution about the broader peptide-drug boom, while the company faces an increasingly aggressive obesity-pill race. Those comments reinforce concerns that future growth may require substantial investment and that competitors could pressure pricing and market share.

Analysts Set New Price Targets

Several brokerages recently commented on NVO. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Berenberg Bank set a $47.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, August 12th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $64.94.

Get Our Latest Report on NVO

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.